Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: January 2, 2005 (53-week fiscal year)
Business Overview: A leading provider of scientific instruments, consumables, and services to pharmaceutical, biomedical, environmental testing, and industrial markets. Operations are organized into three reporting segments: Life and Analytical Sciences, Optoelectronics, and Fluid Sciences.
Key Financial Metrics
| Metric | Fiscal 2004 | Fiscal 2003 |
|---|---|---|
| Total Sales (Continuing Ops) | $1,687.2 million | $1,532.1 million |
| Operating Income | $177.1 million | $141.8 million |
| Net Income | $96.0 million | $53.0 million |
| Diluted EPS | $0.74 | $0.41 |
| Gross Margin | 40.3% | 41.2% |
| Operating Margin | 10.5% | 9.3% |
| Operating Cash Flow | $199.5 million | $163.7 million |
| Total Debt (Short + Long Term) | $374.6 million | $549.5 million |
| Cash and Equivalents | $197.5 million | $191.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 10% year-over-year, driven by a 36% surge in Fluid Sciences sales ($243.8M vs $179.7M) and 9% growth in Optoelectronics. Life and Analytical Sciences grew 6%. Foreign exchange rates (primarily the Euro) contributed approximately $47.1 million to the sales increase.
- Profitability: Operating income rose 25% to $177.1 million. Net income increased 81% to $96.0 million. The effective tax rate decreased to 28.2% from 32.2%, aided by a $10.4 million benefit from resolving an IRS audit.
- Debt Reduction: The company aggressively reduced debt, paying down $175.0 million of its term loan. Total debt decreased significantly from $549.5 million in 2003 to $374.6 million in 2004.
- Discontinued Operations: The company recorded a net loss of $2.2 million from discontinued operations, primarily due to the shutdown of the Electroformed Products and Computer-To-Plate businesses.
Guidance, Outlook, and Risks
- Acquisitions: In February 2005, the company acquired Elcos AG (custom LED solutions) for approximately $15.1 million in cash plus potential earn-outs.
- Capital Expenditures: Expected to range between $25 million and $35 million in 2005, focused on new products and shifting production to lower-cost locations.
- Accounting Changes: The company anticipates adopting SFAS No. 123R (Share-Based Payment) in 2005, which will increase stock compensation expense.
- Legal Proceedings: Significant ongoing litigation includes patent infringement claims by Enzo Biochem/Enzo Life Sciences and Amersham Biosciences regarding high-throughput screening products. A class action lawsuit regarding misleading statements from 2001-2002 remains pending.
- Environmental: An accrual of $3.8 million exists for known environmental matters, with potential exposure not expected to be materially different from recorded amounts.
- Market Risks: Exposure to foreign currency fluctuations, cyclical downturns in semiconductor and aerospace markets, and reliance on key customers.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with financial ratios (leverage, interest coverage) under the senior credit facility and 8 7/8% notes, especially given the high debt load relative to equity.
- Legal Exposure: Monitor the status of the Enzo and Amersham patent litigation, as adverse outcomes could result in significant damages or injunctions.
- Discontinued Operations: Confirm the finalization of costs related to the shutdown of Electroformed Products and Computer-To-Plate businesses.
- Foreign Exchange: Assess the impact of currency fluctuations on future earnings, as 54% of sales are international.
- Stock Compensation: Review the impact of the upcoming SFAS 123R adoption on future net income and EPS.